Premium
LATE assessment of thrombolytic efficacy with alteplase (rt‐PA) six‐24 hours after onset of acute myocardial infarction
Author(s) -
Bett J. H. Nick
Publication year - 1993
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1993.tb04754.x
Subject(s) - medicine , myocardial infarction , placebo , tissue plasminogen activator , infarction , fibrinolytic agent , t plasminogen activator , fibrinolysis , recombinant tissue plasminogen activator , thrombolysis , surgery , cardiology , ischemia , alternative medicine , ischemic stroke , pathology , modified rankin scale
Conflicting results on the benefit of thrombolytic therapy administered six to 24 hours after the onset of myocardial infarction (Ml) led to the LA TE trial. Five thousand seven hundred and eleven patients were treated with recombinant tissue plasminogen activator (t‐PA) or placebo, treatment was begun between six and 24 hours after the onset of infarction. For patients treated within 12 hours, there was a relative reduction in 35 day mortality of 25%, but no benefit for those treated at 12 to 24 hours. The benefits were confined to those whose treatment was begun within three hours of admission to hospital. These results widen the window for effective treatment from six to 12 hours after the onset of infarction, but emphasise the need for expeditious treatment when the diagnosis of MI is suspected. (Aust NZ J Med 1993; 23: 745–748.)